The latest advances in clinical research on the first-line treatment of advanced hepatocellular carcinoma with "Treprizumab + Bevacizumab" are released

On March 20, 2021, the second CSCO-Junshi Bio-Tumor Immunity Summit Forum of "Jun DREAM·Jian Dang Shi" was held in Shanghai.

Immune combination therapy has become a new trend in the treatment of liver cancer

Academician Fan Jia first delivered a speech at the conference.

Speech by Academician Fan Jia, Dean of Zhongshan Hospital Affiliated to Fudan University

Primary liver cancer mainly includes three different pathological types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and HCC-ICC mixed type, of which HCC accounts for 75%-85%.

It is understood that the current treatment methods for primary liver cancer include liver resection, liver transplantation, local ablation therapy, TACE, radiotherapy, systemic therapy and other methods.

"In recent years, emerging immunotherapies represented by anti-PD-1 monoclonal antibody drugs have brought brand-new changes to the systemic treatment of advanced liver cancer.

Phase II study of "Treprizumab + Bevacizumab" in the first-line treatment of advanced liver cancer: initial efficacy, promising trend

The Phase II study of teriprizumab combined with bevacizumab in the first-line treatment of advanced hepatocellular carcinoma is a single-arm, multi-center, open-label clinical study, led by Professor Hao Chunyi of Beijing Cancer Hospital, and carried out in 6 centers across the country .

Professor Hao Chunyi and Professor Chen Yajin from Sun Yat-sen Memorial Hospital of Sun Yat-sen University delivered speeches as researchers.

Professor Hao Chunyi from Peking University Cancer Hospital (left), Professor Chen Yajin from Sun Yat-sen Memorial Hospital of Sun Yat-sen University (middle), and Professor Shang Changzhen from Sun Yat-sen Memorial Hospital of Sun Yat-Sen University (right) made speeches

Professor Shang Changzhen from Sun Yat-sen Memorial Hospital of Sun Yat-sen University introduced the research plan and data results in detail.

The JUPITER-10 Phase III clinical study was officially launched, introducing the Chinese Liver Cancer Staging Program (CNLC)

The JUPITER-10 study launch ceremony was also held at the meeting, announcing the formal launch of a phase III clinical study of teriprizumab combined with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma.

Researchers of JUPITER-10 and Junshi Biology jointly light up the "Music of Life"

The JUPITER-10 study is a multi-center, open-label, randomized controlled international multi-center key registration phase III clinical study, led by Academician Fan Jia, planned to be carried out in mainland China, Taiwan, Singapore and other regions, with a total of 280 A case of patients with hepatocellular carcinoma, aimed at the safety and efficacy of the first-line treatment of Bitreprizumab combined with bevacizumab and sorafenib in the treatment of advanced hepatocellular carcinoma.

In addition to the classic Barcelona staging standard (BCLC), the study design analysis will also introduce the Chinese liver cancer staging standard (CNLC) for efficacy analysis.

As China’s first domestic monoclonal antibody drug targeting PD-1 approved for marketing, Junshi Bio’s independent research and development of teriprizumab has a global layout covering more than ten tumor types, more than 30 single drugs and combination drugs.

Dr.

About Teriplizumab Injection (Tuoyi)

As the first domestically-made monoclonal antibody drug targeting PD-1, Teriplizumab Injection (Tuoyi?) was approved for marketing in my country, and was supported by a major national science and technology project.

In May 2020, the new indications for teriplimumab for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received systemic treatment failure or intolerance were accepted by the NMPA, and will be accepted by the NMPA in July 2020.

Teriplizumab began clinical research and development in early 2016, and has carried out more than 30 clinical studies around the world, actively exploring the use of this product in melanoma, nasopharyngeal cancer, urothelial cancer, lung cancer,The efficacy and safety of gastric cancer , esophageal cancer, liver cancer, cholangiocarcinoma, breast cancer , kidney cancer and other indications, combined therapy cooperation with leading innovative pharmaceutical companies at home and abroad are also underway, and we look forward to bringing more patients from China and other countries Obtained the international advanced level of tumor immunotherapy .